605077 Zhejiang Huakang Pharmaceutical
- 14.21
- +0.07+0.50%
Zhejiang Huakang Pharmaceutical News
Express News | The USA plans to initiate "double anti" investigations against China regarding erythritol, with relevant product prices having already rebounded this year.
Express News | Overview of the A-share restricted stocks lifting: Restricted stocks with a Market Cap of 0.772 billion yuan are lifted today.
Express News | Huakang Co., Ltd.: Currently, the company's Operation situation is normal.
Huakang Corporation (605077.SH): Fujian Yake's shareholding ratio has decreased to 5.00%.
On November 25, Gelonghui reported that Huakang Co., Ltd. (605077.SH) announced that it recently received a "Simplified Equity Change Report" issued by Fujian Yake. From October 16, 2024, to November 22, 2024, Fujian Yake reduced its shareholding in the company by 2,945,814 shares through centralized bidding. After this change in equity, the number of shares held by Fujian Yake decreased from 18,239,858 shares to 15,294,044 shares, and the shareholding ratio dropped from 5.98% to 5.00%.
Huakang Shares (605077): Q3 performance is still under short-term pressure, planning to acquire Yuxin Maltitol to initiate industry consolidation.
The company released the third quarter report for 2024: During the reporting period, the company achieved revenue of 2.106 billion yuan (YoY +3%), net income attributable to parent company of 0.187 billion yuan (YoY -32%), and net income attributable to parent company after non-recurring adjustments of 0.182 billion yuan.
Express News | Nearly 20 A-share listed companies disclosed the latest announcements of mergers and acquisitions this week. cccg real estate corporation plans to acquire 100% equity of cccg service for 0.7 billion yuan.
Express News | Huakang Corporation: Intends to acquire 100% equity of Yuxin Sorbitol, and the stocks will resume trading next Monday.
Huakang Corporation (605077.SH) is planning to purchase all or part of the equity of Yuxin Sorbitol. Stock and bond trading will be suspended from October 28th.
Huakang Co., Ltd. (605077.SH) announced that the company is planning to use a combination of issuing shares and paying cash for...
Express News | Huakang Group: Planning to issue stocks and pay cash to acquire assets. Stock trading suspended.
Huakang Stock Report for the Third Quarter of 2024
Announcement of Huakang Co., Ltd. on major operating data from January to September 2024
Express News | Huakang Co., Ltd.: Shareholder Fujian Yakexi plans to reduce its shareholding by no more than 1.00%.
Huakang Corporation (605077): Profit under pressure, waiting for the new production capacity to be implemented.
Investment highlights for Q2 2024: Revenue reached 0.724 billion yuan, a year-on-year increase of 1%. Looking at the first half of 2024, the company achieved revenue of 1.359 billion yuan, a year-on-year decrease of 1%, and achieved a net income attributable to shareholders of 0.138 billion yuan, a year-on-year decrease of 2%.
Huakang Co. (605077): Short-term performance under pressure, looking forward to the completion of the Zhoushan project construction.
Event: The company released its 2024 interim report, achieving a revenue of 1.36 billion yuan, a year-on-year decrease of 0.7%; net income attributable to shareholders of 0.14 billion yuan, a year-on-year decrease of 25.3%. In the second quarter of 2024, the company achieved a revenue of 0.72 billion yuan.
Summary of Huakang Corporation's 2024 Interim Report
Huakang Group 2024 Interim Report
Huakang Corporation (605077.SH): Granted 0.845 million shares of reserved restricted stocks to incentive recipients.
On August 21, GeLongHui announced that HuaKang Corporation (605077.SH) has agreed to reserve restricted stocks to 25 incentive recipients, with a total of 0.845 million shares to be granted on August 21, 2024, at a price of 9.14 yuan per share.
Huakang Corporation (605077.SH): The net income in the first half of the year was 0.138 billion yuan, a year-on-year decrease of 25.27%.
Huakang Corporation (605077.SH) announced its half-year report for 2024 on August 21. During the reporting period, the company achieved revenue of 1.359 billion yuan, a decrease of 0.73% compared to the same period last year. The net income attributable to shareholders of the listed company was 0.138 billion yuan, a decrease of 25.27% compared to the same period last year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.13 billion yuan, a decrease of 32.20% compared to the same period last year. The basic earnings per share were 0.46 yuan. The decrease in net income is mainly due to the amortization expense of stock-based incentives this period and the increase in expenses during the construction phase of Huakang project in Zhoushan.
Huakang Corporation (605077.SH): Actual controller renewed the consistent action agreement.
On August 8th, Gelunhui reported that Huakang (605077.SH) received notice from Mr. Chen Deshui, Mr. Cheng Xinping, Mr. Yu Jianming, and Mr. Xu Xiaorong (hereinafter referred to as "Parties") that due to the expiration of the "Agreement on Joint Control of Zhejiang Huakang Pharmaceutical Co., Ltd. and Maintaining Consistent Action" (hereinafter referred to as the "Consistency Agreement") signed by the Parties in June 2017, in order to maintain the stability of the company's actual control and the consistency of significant decision-making, the Parties officially renewed the Consistency Agreement through friendly negotiations, and there was no change in the actual controller.
Express News | Huakang Stock: Subsidiary GaoMi TongLi fined for excessive pollution
No Data
